3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
19
Paclitaxel
6
Trastuzumab
5
Nivolumab
5
palbociclib
4
Carboplatin
4
Biopsy
4
lenvatinib
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Immunoglobulin G
3
Fulvestrant
3
Cyclophosphamide
3
Cetuximab
3
trastuzumab deruxtecan
2
tisotumab vedotin
2
spartalizumab
2
sargramostim
2
gedatolisib
2
fludarabine
2
epacadostat
2
capivasertib
2
X-Rays
2
Sunitinib
2
Docetaxel
2
Disulfides
2
Cisplatin
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Diphenhydramine
×
Head & Neck
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled